Recombinant Human Elongin B/Elongin C/VHL Complex, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Elongin B/Elongin C/VHL Complex, CF Summary

• Details of Functionality: Typical protein concentration for use in vitro will depend on experimental conditions.
• Source: Spodoptera frugiperda, Sf 21 (baculovirus)-derived human ELOB/ELOC/VHL Complex protein
  Met1 - Gln118 (ELOB), Met1 - Cys112 (ELOC), Met1 - Asp213 (VHL)
• Accession #: Q15370.1 (ELOB), Q15369.1 (ELOC), P40337.2 (VHL)
• Protein/Peptide Type: Recombinant Enzymes

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 24 kDa (VHL), 13.1 kDa (ELOB), 12.8 kDa (ELOC).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -70 °C as supplied.
  • 3 months, -70 °C under sterile conditions after opening.
• Buffer: Supplied as a solution in HEPES, NaCl, DTT and Glycerol.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Elongin B/Elongin C/VHL Complex, CF

• ELOB/ELOC/VHL Complex
• Elongin B/Elongin C/VHL Complex

Background

Together, Elongin B (ELOB) and Elongin C (ELOC) form a heterodimer that serves as the regulatory subunit for the Elongin complex--a general transcription elongation factor that increases RNA Polymerase II transcription through template-encoded arresting sites.  The ELOB/ELOC complex also binds to the "BC-box motif" found in many proteins in the VHL-box and SOCS-box protein families.  In this function, ELOB/ELOC serves as an adapter between substrate recognition proteins and either Cullin-2/Rbx1 (in VHL-box E3 Ubiquitin ligases) or Cullin-5/Rbx2 (in SOCS-box E3 Ubiquitin ligases).  VHL (von Hippel-Lindau disease tumor suppressor) is the substrate recognition subunit for an E3 ligase activity that ubiquitinates proteins containing hydroxyproline residues.  Targets of VHL include HIF1 alpha , beta 2 adrenergic receptor, ZHX2 and others.  

1. Kamura T., et al.  (1998) Genes Dev. 12:3872.
2. Okumura F., et al.  (2012) Front. Oncol. 2:10.
3. Xie L., et al.  (2009) Sci. Signal. 2:ra33.
4. Zhang J. et al.  (2018) Science 361:290. 

Publications for ELOB/ELOC/VHL Complex (E3-600)(2)

Publications using E3-600

• Liu, S;Tong, B;Mason, JW;Ostrem, JM;Tutter, A;Hua, BK;Tang, SA;Bonazzi, S;Briner, K;Berst, F;Zécri, FJ;Schreiber, SL; Rational screening for cooperativity in small-molecule inducers of protein-protein associations bioRxiv : the preprint server for biology 2023-05-24 [PMID: 37292909] (Bioassay, N/A)
• Y Xiong, Y Zhong, H Yim, X Yang, KS Park, L Xie, PI Poulikakos, X Han, Y Xiong, X Chen, J Liu, J Jin Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets Journal of the American Chemical Society, 2022-11-30;0(0):. 2022-11-30 [PMID: 36448571] (Pull-Down Assay, Human)

Bioinformatics

• Uniprot:
  • Q15370.1 (ELOB), Q15369.1 (ELOC), P40337.2 (VHL)()